A M Buchanan-Hughes1, M Buti2,3, K Hanman4, B Langford4, M Wright5, L A Eddowes4. 1. Costello Medical Consulting Ltd, Cambridge, UK. amy.buchanan-hughes@costellomedical.com. 2. Hospital Universitario Valle Hebron, Barcelona, Spain. 3. Ciberehd del Instituto Carlos III, Madrid, Spain. 4. Costello Medical Consulting Ltd, Cambridge, UK. 5. University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Abstract
PURPOSE: Chronic hepatitis C infection and its treatment can considerably affect patients' health-related quality-of-life (HRQoL). This study aimed to identify and summarise the current evidence base for health state utility values (HSUVs) in patients with chronic hepatitis C infection, generated using the EuroQol 5-dimensions (EQ-5D) questionnaire. METHODS: MEDLINE, Embase, the Cochrane Library and EconLit were searched from database inception through 31 August 2017. Eligible studies reported HSUVs elicited using the EQ-5D questionnaire in adults with chronic hepatitis C infection. Study quality and risk of bias were assessed. RESULTS: Of 1480 records identified, 26 studies were included. The most commonly defined health states described different stages of chronic hepatitis C infection and specific liver-related disease states, including METAVIR score, compensated and decompensated cirrhosis, hepatocellular carcinoma and liver transplantation. Patients with higher METAVIR scores tended to have lower EQ-5D scores compared to patients with lower METAVIR scores. Patients that achieved sustained virologic responses tended to have higher EQ-5D scores compared to those that did not. A meta-analysis conducted on three studies confirmed that patients with decompensated cirrhosis have significantly lower HSUVs than patients with compensated cirrhosis [mean difference - 0.11 (95% CI - 0.19 to - 0.04)], implying worse HRQoL. However, there was not sufficient evidence to compare how different treatments for chronic hepatitis C infection affect EQ-5D scores. CONCLUSIONS: This study provides a summary of EQ-5D HSUVs for patients with chronic hepatitis C infection, and demonstrates that clinically important disease stages associated with treatment decisions are associated with differences in HRQoL.
PURPOSE:Chronic hepatitis C infection and its treatment can considerably affect patients' health-related quality-of-life (HRQoL). This study aimed to identify and summarise the current evidence base for health state utility values (HSUVs) in patients with chronic hepatitis C infection, generated using the EuroQol 5-dimensions (EQ-5D) questionnaire. METHODS: MEDLINE, Embase, the Cochrane Library and EconLit were searched from database inception through 31 August 2017. Eligible studies reported HSUVs elicited using the EQ-5D questionnaire in adults with chronic hepatitis C infection. Study quality and risk of bias were assessed. RESULTS: Of 1480 records identified, 26 studies were included. The most commonly defined health states described different stages of chronic hepatitis C infection and specific liver-related disease states, including METAVIR score, compensated and decompensated cirrhosis, hepatocellular carcinoma and liver transplantation. Patients with higher METAVIR scores tended to have lower EQ-5D scores compared to patients with lower METAVIR scores. Patients that achieved sustained virologic responses tended to have higher EQ-5D scores compared to those that did not. A meta-analysis conducted on three studies confirmed that patients with decompensated cirrhosis have significantly lower HSUVs than patients with compensated cirrhosis [mean difference - 0.11 (95% CI - 0.19 to - 0.04)], implying worse HRQoL. However, there was not sufficient evidence to compare how different treatments for chronic hepatitis C infection affect EQ-5D scores. CONCLUSIONS: This study provides a summary of EQ-5D HSUVs for patients with chronic hepatitis C infection, and demonstrates that clinically important disease stages associated with treatment decisions are associated with differences in HRQoL.
Entities:
Keywords:
EQ-5D; HCV; Hepatitis C; QoL; Quality of life; Utility
Authors: Jennifer Uyei; Tamar H Taddei; David E Kaplan; Michael Chapko; Elizabeth R Stevens; R Scott Braithwaite Journal: PLoS One Date: 2019-08-26 Impact factor: 3.240
Authors: Carolina Rosadas; Tatiane Assone; Marina Yamashita; Adine Adonis; Marzia Puccioni-Sohler; Marisa Santos; Arthur Paiva; Jorge Casseb; Augusto C P Oliveira; Graham P Taylor Journal: PLoS Negl Trop Dis Date: 2020-10-16
Authors: Hui Jun Zhou; Jing Cao; Hui Shi; Nasheen Naidoo; Sherehe Semba; Pei Wang; Yi Fan Fan; Shui Cheng Zhu Journal: Front Public Health Date: 2021-12-09